drugset
Drugs / VRC-HIVDNA016-00-VP
last change Nov 2017 re-read 9 days ago

VRC-HIVDNA016-00-VP

also known as HIV DNA prime vaccine

Vaccine

Developed for
HIV infectious disease
Investigated by
National Institute of Allergy and Infectious Diseases (NIAID) · International AIDS Vaccine Initiative · Centers for Disease Control and Prevention · HIV Vaccine Trials Network · Merck Sharp & Dohme LLC · Objectif Recherche Vaccins SIDA
+5 more · Pfizer · Robert L. Murphy · US Military HIV Research Program · United States Department of Defense · Vaccine Research Center

Trials 12

today NCT01386489 · Ph 1 NCT00955006 · Ph 1 NCT00976404 · Ph 2 NCT00123968 · Ph 1/2 NCT00321061 · Ph 1 NCT00270465 · Ph 1 NCT00124007 · Ph 1 NCT00125970 · Ph 2 NCT00109629 · Ph 1 NCT00089531 · Ph 1
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 17 trials
Phase 1 NCT01386489 Jun 2011 → Mar 2014 — National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT00955006 May 2011 → Sep 2013 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT00321061 Apr 2006 → Dec 2009 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT00270465 Dec 2005 → Jun 2009 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT00124007 Nov 2005 → Apr 2007 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT00109629 Apr 2005 → Jan 2008 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT00089531 Aug 2004 → Jan 2008 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT00123968 May 2006 → Jun 2012 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 24 trials · 1 missed
Phase 2 NCT00976404 Nov 2009 → Jul 2013 HIV infectious disease Robert L. Murphy Completed Missed primary
Phase 2 NCT00125970 Sep 2005 → Feb 2008 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 2 NCT00415649 — HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Withdrawn No outcome recorded
Phase 2 NCT00498056 — HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Withdrawn No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 12 sources stand behind the page.

FieldValueCited text
Known as VRC-HIVDNA016-00-VP “receive antiretroviral therapy intensification alone or intensification plus injections of HIV DNA prime vaccine (4 mg VRC-HIVDNA016-00-VP) at weeks 8, 12, and 16, followed by...” PMID 26424549 ↗ Feb 2015
12

“This study will evaluate the safety and immunogenicity of an experimental multiclade HIV vaccine, VRC-HIVDNA016-00-VP, followed by a similarly structured adenovirus-vectored...” NCT00955006 ↗

“The vaccines used in this study are known as VRC-HIVDNA016-00-VP (called the "DNA vaccine") and VRC-HIVADV014-00-VP (called the "rAd5 vaccine").” NCT00321061 ↗

NCT01386489 ↗

NCT00498056 ↗

NCT00270465 ↗

NCT00089531 ↗

NCT00125970 ↗

NCT00124007 ↗

NCT00123968 ↗

NCT00109629 ↗

Show 2 more sources
Known as HIV DNA prime vaccine “receive antiretroviral therapy intensification alone or intensification plus injections of HIV DNA prime vaccine (4 mg VRC-HIVDNA016-00-VP) at weeks 8, 12, and 16, followed by...” PMID 26424549 ↗ Feb 2015
Modality Vaccine “a 6-plasmid multiclade HIV-1 DNA vaccine, VRC-HIVDNA016-00-VP” NCT00089531 ↗
Route Intramuscular “Each DNA vaccination will be 1 mL of vaccine administered intramuscularly (in deltoid muscle)” NCT00089531 ↗